Immunovant, Inc. (IMVT) News
Track canonical SquawkNews coverage tagged to IMVT, Immunovant, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
IMVT - Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
IMVT - Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
EARNINGS | Aug 06, 2026, 11:01 AM UTC
L
Citigroup Maintains Buy on Immunovant, Raises Price Target to $61
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ: IMVT ) with a Buy and raises the price target from $57 to $61.
EQUITY | Jun 30, 2026, 06:49 PM UTC